• catheter ablation
• ventricular tachycardia

Ventricular Tachycardia (VT) ablation has emerged in last decades as an increasingly used therapeutic approach for the treatment of VT. In our study, we analyzed several aspects of a large single center cohort of patients who underwent VT ablation (99 patients, 17% female, mean age 65±15 y, mean LVEF 44 ± 13%). 40% of the patients presented in electrical storm. We wanted to focus on safety issues and efficacy results, as well as analyze potential predictors of efficacy in terms of VT recurrence. Overall, in our experience VT ablation appeared as a safe and effective procedure, with no intraoperative life-threatening complications and a rate of major adverse events in line with the main previous studies (3%). During a median follow up of 593 days (IQR [181-985]), 60% of the patients were free from VT recurrence. There was no significant difference in VT recurrence between ischemic and non ischemic patients (40% of VT recurrence in ischemic patients and 46% in non ischemic patients; p 0,576). In 75% of the patients that were not in anticoagulant treatment before ablation, a temporary post-procedure anticoagulation was established. In 20% of the patients in amiodarone therapy, drug treatment was disrupted. Interestingly, substrate VT ablation approach via conducting channel technique was a significant predictor of VT ablation efficacy at univariate analysis (H.R. 0,208, 95%C.I 0,500-0,868, p 0,031), with a trend towards significance at multivariate analysis (H.R. 0,250, 95%C.I 0,058-1,073, p 0,062).